Soni Shaikh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Soni Shaikh has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Tapati Chakraborti
University of Kalyani
6 shared publicationsAnimesh Chowdhury
University of Kalyani
5 shared publicationsPulak Kar
Department of Biochemistry and Biophysics, University of Kalyani, Kalyani, India
4 shared publications- Sajal Chakraborti
University of Kalyani
4 shared publications Soumitra Roy
University of Kalyani
4 shared publicationsKrishna Samanta
Department of Biochemistry and Biophysics, University of Kalyani, Kalyani, India
3 shared publications
Latest Publications
- 25 July 2024
- Published by Elsevier in Indian Journal of Tuberculosis
- Vol. 72 (1) , 103-111
Briefing of pulmonary sarcoidosis: Reduction-oxidation, misleading and possibilities
- 25 July 2024
- Published by Elsevier in Indian Journal of Tuberculosis
- Vol. 72 (1) , 103-111
Briefing of pulmonary sarcoidosis: Reduction-oxidation, misleading and possibilities
- 4 August 2021
- Published by Springer Nature
- p. 1-19
Reactive Species and ER-Mitochondrial Performance for Glioblastoma Multiforme Treatment Strategy
- 4 August 2021
- Published by Springer Nature
- p. 1-19
Reactive Species and ER-Mitochondrial Performance for Glioblastoma Multiforme Treatment Strategy
- 15 October 2019
- Published by Elsevier in Current Molecular Pharmacology
- Vol. 12 (4) , 261-271
Bafilomycin-A1 and ML9 Exert Different Lysosomal Actions to Induce Cell Death
Objective: Bafilomycin-A1 and ML9 are lysosomotropic agents, irrespective of cell types. However, the mechanisms of lysosome targeting either bafilomycin-A1 or ML9 are unclear.Methods: The present research has been carried out by different molecular and biochemical analyses like western blot, confocal imaging and FACS studies, as well as molecular docking.Results: Our data shows that pre-incubation of neonatal cardiomyocytes with ML9 for 4h induced cell death, whereas a longer period of time (24h) with bafilomycin-A1 was required to induce an equivalent effect. Neither changes in ROS nor ATP production is associated with such death mechanisms. Flow cytometry, LC3-II expression levels, and LC3-GFP puncta formation revealed a similar lysosomotropic effect for both compounds. We used a molecular docking approach, that predicts a stronger inhibitory activity against V-ATPase-C1 and C2 domains for bafilomycin-A1 in comparison to ML9.Conclusion: Bafilomycin-A1 and ML9 are lysosomotropic agents, involved in cell death events. But such death events are not associated with ATP and ROS production. Furthermore, both the drugs target lysosomes through different mechanisms. For the latter, cell death is likely due to lysosomal membrane permeabilization and release of lysosomal proteases into the cytosol.
- 15 October 2019
- Published by Elsevier in Current Molecular Pharmacology
- Vol. 12 (4) , 261-271
Bafilomycin-A1 and ML9 Exert Different Lysosomal Actions to Induce Cell Death
Objective: Bafilomycin-A1 and ML9 are lysosomotropic agents, irrespective of cell types. However, the mechanisms of lysosome targeting either bafilomycin-A1 or ML9 are unclear.Methods: The present research has been carried out by different molecular and biochemical analyses like western blot, confocal imaging and FACS studies, as well as molecular docking.Results: Our data shows that pre-incubation of neonatal cardiomyocytes with ML9 for 4h induced cell death, whereas a longer period of time (24h) with bafilomycin-A1 was required to induce an equivalent effect. Neither changes in ROS nor ATP production is associated with such death mechanisms. Flow cytometry, LC3-II expression levels, and LC3-GFP puncta formation revealed a similar lysosomotropic effect for both compounds. We used a molecular docking approach, that predicts a stronger inhibitory activity against V-ATPase-C1 and C2 domains for bafilomycin-A1 in comparison to ML9.Conclusion: Bafilomycin-A1 and ML9 are lysosomotropic agents, involved in cell death events. But such death events are not associated with ATP and ROS production. Furthermore, both the drugs target lysosomes through different mechanisms. For the latter, cell death is likely due to lysosomal membrane permeabilization and release of lysosomal proteases into the cytosol.
- 1 July 2019
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 25 (7) , 571-584
The Hard-To-Close Window of T-Type Calcium Channels
- 1 July 2019
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 25 (7) , 571-584
The Hard-To-Close Window of T-Type Calcium Channels
- 1 April 2018
- Published by Elsevier in Toxicology in Vitro
- Vol. 48, 121-127
The STIM1 inhibitor ML9 disrupts basal autophagy in cardiomyocytes by decreasing lysosome content
- 1 April 2018
- Published by Elsevier in Toxicology in Vitro
- Vol. 48, 121-127
The STIM1 inhibitor ML9 disrupts basal autophagy in cardiomyocytes by decreasing lysosome content
- Open Access
- 31 January 2018
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 78 (3) , 603-609
T-type Ca2+ Channels: T for Targetable
In the past decade, T-type Ca2+ channels (TTCC) have been unveiled as key regulators of cancer cell biology and thus have been proposed as chemotherapeutic targets. Indeed, in vitro and in vivo studies indicate that TTCC pharmacologic blockers have a negative impact on the viability of cancer cells and reduce tumor size, respectively. Consequently mibefradil, a TTCC blocker approved in 1997 as an antihypertensive agent but withdrawn in 1998 because of drug–drug interactions, was granted 10 years later the orphan drug status by the FDA to investigate its efficacy against brain, ovary, and pancreatic cancer. However, the existence of different channel isoforms with distinct physiologic roles, together with the lack of selective pharmacologic agents, has hindered a conclusive chemotherapeutic evaluation. Here, we review the available evidence on TTCC expression, value as prognostic markers, and effectiveness of their pharmacologic blockade on cancer cells in vitro and in preclinical models. We additionally summarize the status of clinical trials using mibefradil against glioblastoma multiforme. Finally, we discuss the future perspectives and the importance of further development of multidisciplinary research efforts on the consideration of TTCCs as biomarkers or targetable molecules in cancer. Cancer Res; 78(3); 1–7. ©2018 AACR.
- 31 January 2018
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 78 (3) , 603-609
Open AccessT-type Ca2+ Channels: T for Targetable
In the past decade, T-type Ca2+ channels (TTCC) have been unveiled as key regulators of cancer cell biology and thus have been proposed as chemotherapeutic targets. Indeed, in vitro and in vivo studies indicate that TTCC pharmacologic blockers have a negative impact on the viability of cancer cells and reduce tumor size, respectively. Consequently mibefradil, a TTCC blocker approved in 1997 as an antihypertensive agent but withdrawn in 1998 because of drug–drug interactions, was granted 10 years later the orphan drug status by the FDA to investigate its efficacy against brain, ovary, and pancreatic cancer. However, the existence of different channel isoforms with distinct physiologic roles, together with the lack of selective pharmacologic agents, has hindered a conclusive chemotherapeutic evaluation. Here, we review the available evidence on TTCC expression, value as prognostic markers, and effectiveness of their pharmacologic blockade on cancer cells in vitro and in preclinical models. We additionally summarize the status of clinical trials using mibefradil against glioblastoma multiforme. Finally, we discuss the future perspectives and the importance of further development of multidisciplinary research efforts on the consideration of TTCCs as biomarkers or targetable molecules in cancer. Cancer Res; 78(3); 1–7. ©2018 AACR.
- 15 April 2016
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 310 (8) , E587-E596
Regulation of cardiomyocyte autophagy by calcium
Calcium signaling plays a crucial role in a multitude of events within the cardiomyocyte, including cell cycle control, growth, apoptosis, and autophagy. With respect to calcium-dependent regulation of autophagy, ion channels and exchangers, receptors, and intracellular mediators play fundamental roles. In this review, we discuss calcium-dependent regulation of cardiomyocyte autophagy, a lysosomal mechanism that is often cytoprotective, serving to defend against disease-related stress and nutrient insufficiency. We also highlight the importance of the subcellular distribution of calcium and related proteins, interorganelle communication, and other key signaling events that govern cardiomyocyte autophagy.
- 15 April 2016
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 310 (8) , E587-E596
Regulation of cardiomyocyte autophagy by calcium
Calcium signaling plays a crucial role in a multitude of events within the cardiomyocyte, including cell cycle control, growth, apoptosis, and autophagy. With respect to calcium-dependent regulation of autophagy, ion channels and exchangers, receptors, and intracellular mediators play fundamental roles. In this review, we discuss calcium-dependent regulation of cardiomyocyte autophagy, a lysosomal mechanism that is often cytoprotective, serving to defend against disease-related stress and nutrient insufficiency. We also highlight the importance of the subcellular distribution of calcium and related proteins, interorganelle communication, and other key signaling events that govern cardiomyocyte autophagy.
- 13 November 2013
- Published by Springer Nature
- p. 49-62
Exercise and Matrix Metalloproteases in Health and Disease: A Brief Overview
- 13 November 2013
- Published by Springer Nature
- p. 49-62
Exercise and Matrix Metalloproteases in Health and Disease: A Brief Overview
- 1 November 2013
- Published by Springer Nature
- p. 351-364
Matrix Metalloprotease-2 in the Development and Progression of Cardiovascular Diseases
- 1 November 2013
- Published by Springer Nature
- p. 351-364
Matrix Metalloprotease-2 in the Development and Progression of Cardiovascular Diseases
- 1 October 2012
- Vol. 49 (5) , 316-28
Implications of calpains in health and diseases.
The number of mammalian calpain protease family members has grown as many as 15 till recent count. Although initially described as a cytosolic protease, calpains have now been found in almost all subcellular locations i.e., from mitochondria to endoplasmic reticulum and from caveolae to Golgi bodies. Importantly, some calpains do not possess the 28 kDa regulatory subunit and have only the 80 kDa catalytic subunit. In some instances, the 80 kDa subunit by itself confers the calpain proteolytic activity. Calpains have been shown to be involved in a number of physiological processes such as cell cycle progression, remodeling of cytoskeletal-cell membrane attachments, signal transduction, gene expression and apoptosis. Recent studies have linked calpain deficiencies or it's over production with a variety of diseases, such as muscular dystrophies, gastropathy, diabetes, Alzheimer's and Parkinson's diseases, atherosclerosis and pulmonary hypertension. Herein, we present a brief overview on some implications of calpains on human health and some diseases.
- 1 October 2012
- Vol. 49 (5) , 316-28
Implications of calpains in health and diseases.
The number of mammalian calpain protease family members has grown as many as 15 till recent count. Although initially described as a cytosolic protease, calpains have now been found in almost all subcellular locations i.e., from mitochondria to endoplasmic reticulum and from caveolae to Golgi bodies. Importantly, some calpains do not possess the 28 kDa regulatory subunit and have only the 80 kDa catalytic subunit. In some instances, the 80 kDa subunit by itself confers the calpain proteolytic activity. Calpains have been shown to be involved in a number of physiological processes such as cell cycle progression, remodeling of cytoskeletal-cell membrane attachments, signal transduction, gene expression and apoptosis. Recent studies have linked calpain deficiencies or it's over production with a variety of diseases, such as muscular dystrophies, gastropathy, diabetes, Alzheimer's and Parkinson's diseases, atherosclerosis and pulmonary hypertension. Herein, we present a brief overview on some implications of calpains on human health and some diseases.